These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 33207229)

  • 1. Tentative clinical breakpoints and epidemiological cut-off values of nemonoxacin for Streptococcus pneumoniae and Staphylococcus aureus isolates associated with community-acquired pneumonia.
    Jean SS; Chang LW; Hsueh PR
    J Glob Antimicrob Resist; 2020 Dec; 23():388-393. PubMed ID: 33207229
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro activity of nemonoxacin (TG-873870), a novel non-fluorinated quinolone, against clinical isolates of Staphylococcus aureus, enterococci and Streptococcus pneumoniae with various resistance phenotypes in Taiwan.
    Chen YH; Liu CY; Lu JJ; King CH; Hsueh PR
    J Antimicrob Chemother; 2009 Dec; 64(6):1226-9. PubMed ID: 19833635
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Integrative population pharmacokinetic/pharmacodynamic analysis of nemonoxacin capsule in Chinese patients with community-acquired pneumonia.
    Chen Y; Wu X; Tsai C; Chang L; Yu J; Cao G; Guo B; Shi Y; Zhu D; Hu F; Yuan J; Liu Y; Zhao X; Zhang Y; Wu J; Zhang J
    Front Pharmacol; 2023; 14():912962. PubMed ID: 36923351
    [No Abstract]   [Full Text] [Related]  

  • 4. Integrated safety summary of phase II and III studies comparing oral nemonoxacin and levofloxacin in community-acquired pneumonia.
    Cheng SL; Wu RG; Chuang YC; Perng WC; Tsao SM; Chang YT; Chang LW; Hsu MC
    J Microbiol Immunol Infect; 2019 Oct; 52(5):743-751. PubMed ID: 30616912
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nemonoxacin has potent activity against gram-positive, but not gram-negative clinical isolates.
    Li ZX; Liu YN; Wang R; Li AM
    Clin Ter; 2015; 166(6):e374-80. PubMed ID: 26794819
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The integrated use of pharmacokinetic and pharmacodynamic models for the definition of breakpoints.
    Stass H; Dalhoff A
    Infection; 2005 Dec; 33 Suppl 2():29-35. PubMed ID: 16518709
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics and Pharmacodynamics of Nemonoxacin in a Neutropenic Murine Lung Infection Model Against
    Li X; Chen Y; Xu X; Li Y; Fan Y; Liu X; Bian X; Wu H; Zhao X; Feng M; Guo B; Zhang J
    Front Pharmacol; 2021; 12():658558. PubMed ID: 34017256
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic/Pharmacodynamic Evaluation of a Novel Aminomethylcycline Antibiotic, KBP-7072, in the Neutropenic Murine Pneumonia Model against Staphylococcus aureus and Streptococcus pneumoniae.
    Lepak AJ; Zhao M; Liu Q; Wang P; Wang Y; Bader JC; Ambrose PG; Andes DR
    Antimicrob Agents Chemother; 2019 Mar; 63(3):. PubMed ID: 30559140
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Review of nemonoxacin with special focus on clinical development.
    Qin X; Huang H
    Drug Des Devel Ther; 2014; 8():765-74. PubMed ID: 25045247
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Setting of the tentative epidemiological cut-off values of contezolid for Staphylococcus aureus, Enterococcus faecalis, Enterococcus faecium, Streptococcus pneumoniae and Streptococcus agalactiae.
    Guo Y; Han R; Zhang G; Yang Q; Xue F; Li Y; Zhu D; Hu F
    J Antimicrob Chemother; 2023 Apr; 78(4):1055-1058. PubMed ID: 36849586
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nemonoxacin (TG-873870) for treatment of community-acquired pneumonia.
    Lai CC; Lee KY; Lin SW; Chen YH; Kuo HY; Hung CC; Hsueh PR
    Expert Rev Anti Infect Ther; 2014 Apr; 12(4):401-17. PubMed ID: 24579813
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nemonoxacin dosage adjustment in patients with severe renal impairment based on population pharmacokinetic and pharmacodynamic analysis.
    Li Y; Lu J; Kang Y; Xu X; Li X; Chen Y; Wang K; Liu X; Fan Y; Wu H; Wang Y; Hu J; Yu J; Wu J; Guo B; Zhang Y; Zeng X; Zhao M; Xue J; Zhang J
    Br J Clin Pharmacol; 2021 Dec; 87(12):4636-4647. PubMed ID: 33928669
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selected Mutations by Nemonoxacin and Fluoroquinolone Exposure Among Relevant Gram-Positive Bacterial Strains in Taiwan.
    Yang JJ; Cheng A; Tai HM; Chang LW; Hsu MC; Sheng WH
    Microb Drug Resist; 2020 Feb; 26(2):110-117. PubMed ID: 31478786
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized, double-blind, multicenter Phase II study comparing the efficacy and safety of oral nemonoxacin with oral levofloxacin in the treatment of community-acquired pneumonia.
    Liu Y; Zhang Y; Wu J; Zhu D; Sun S; Zhao L; Wang X; Liu H; Ren Z; Wang C; Xiu Q; Xiao Z; Cao Z; Cui S; Yang H; Liang Y; Chen P; Lv Y; Hu C; Lv X; Liu S; Kuang J; Li J; Wang D; Chang L
    J Microbiol Immunol Infect; 2017 Dec; 50(6):811-820. PubMed ID: 26748734
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of nemonoxacin versus levofloxacin for community-acquired pneumonia.
    van Rensburg DJ; Perng RP; Mitha IH; Bester AJ; Kasumba J; Wu RG; Ho ML; Chang LW; Chung DT; Chang YT; King CH; Hsu MC
    Antimicrob Agents Chemother; 2010 Oct; 54(10):4098-106. PubMed ID: 20660689
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
    Lin L; Chang LW; Tsai CY; Hsu CH; Chung DT; Aronstein WS; Ajayi F; Kuzmak B; Lyon RA
    Antimicrob Agents Chemother; 2010 Jan; 54(1):405-10. PubMed ID: 19884368
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and efficacy of oral nemonoxacin versus levofloxacin in treatment of community-acquired pneumonia: A phase 3, multicenter, randomized, double-blind, double-dummy, active-controlled, non-inferiority trial.
    Yuan J; Mo B; Ma Z; Lv Y; Cheng SL; Yang Y; Tong Z; Wu R; Sun S; Cao Z; Wu J; Zhu D; Chang L; Zhang Y;
    J Microbiol Immunol Infect; 2019 Feb; 52(1):35-44. PubMed ID: 30181096
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro activities of novel nonfluorinated quinolones PGE 9262932 and PGE 9509924 against clinical isolates of Staphylococcus aureus and Streptococcus pneumoniae with defined mutations in DNA gyrase and topoisomerase IV.
    Jones ME; Critchley IA; Karlowsky JA; Blosser-Middleton RS; Schmitz FJ; Thornsberry C; Sahm DF
    Antimicrob Agents Chemother; 2002 Jun; 46(6):1651-7. PubMed ID: 12019071
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Surveillance of omadacycline activity tested against clinical isolates from the United States and Europe: Results from the SENTRY Antimicrobial Surveillance Programme, 2017.
    Huband MD; Pfaller MA; Shortridge D; Flamm RK
    J Glob Antimicrob Resist; 2019 Dec; 19():56-63. PubMed ID: 30825698
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of Delafloxacin versus Moxifloxacin against Bacterial Respiratory Pathogens in Adults with Community-Acquired Bacterial Pneumonia (CABP): Microbiology Results from the Delafloxacin Phase 3 CABP Trial.
    McCurdy S; Keedy K; Lawrence L; Nenninger A; Sheets A; Quintas M; Cammarata S
    Antimicrob Agents Chemother; 2020 Feb; 64(3):. PubMed ID: 31844013
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.